OSMT - Adamas: Positive Reaction To Encouraging Q2 Earnings Report
Adamas Pharmaceuticals (ADMS) recently announced their Q2 earnings report that disclosed that the company beat on GAAP EPS by $0.12, but missed by $0.11M on revenue. During the earnings call, the company publicized their two priorities for the remainder of 2019. One, driving towards the commercial success of GOCOVRI in patients with Parkinson’s disease “PD.” Two, providing top-line Phase III data for GOCOVRI in multiple sclerosis patients with walking impairment “MS-Walking.” Despite the 67.6% year-over-year revenue growth, I was expecting another decimation of the share price. However, the stock performed quite well in